CureVac CEO Franz-Werner Haas said on Thursday the company expects to get its coronavirus vaccine candidate approved in the European Union in June, APA reports citing Teletrader.
Speaking to CNBC, Haas noted that CureVac expects to complete the recruitment for late-stage clinical trials by late April or early May. "So we expect to be given approval, depending on the data certainly, in the beginning of June," he added.
In February, the European Medicines Agency (EMA) started a rolling review of CureVac's vaccine candidate CVnCoV. At the time, the agency said non-clinical data and early clinical results showed that the vaccine triggers the production of COVID-19 antibodies.